Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant females who are 12 years of age and older.~* Documented clinical history of SAR (for at least 2 years preceding the Screening Visit \[Visit 1\]) with exacerbations (clinical evidence of active symptoms) for the relevant seasonal allergen during the Fall or mountain cedar allergy seasons (e.g., ragweed or mountain cedar pollen)~* A 12-hour rTNSS ≥8 out of a possible 12 and a congestion score ≥2 for the AM assessment at the Screening Visit (Visit 1).~Exclusion Criteria:~* Pregnant or lactating women.~* History of anaphylaxis and/or other severe local reaction(s) to skin testing.~* History of positive test for HIV, Hepatitis B or Hepatitis C infection.~* Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.~* Subjects with an active pulmonary disorder or infection.~* Subjects with posterior subcapsular cataracts or glaucoma~* Plans to travel outside the known pollen area for the investigational site for 24 hours or longer during the last 7 days of the run-in period.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSP 301 NS (Type: EXPERIMENTAL): None
- GOM-NS (Type: ACTIVE_COMPARATOR): None
- GMM-2 NS (Type: ACTIVE_COMPARATOR): None
- GSP 301 placebo NS (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).